Skip to main content Skip to search Skip to main navigation

FDA: Launch of “Elsa” AI Tool

The U.S. Food and Drug Administration (FDA) has launched Elsa, a generative AI tool aimed at enhancing the productivity of its employees, from scientists to investigators.

Key Highlights:

  • Accelerated Rollout:
    • Launched ahead of the June 30 target
    • Delivered under budget, thanks to cross-agency collaboration
  • Secure & Private:
    • Built within a high-security GovCloud
    • Does not train on data from regulated industries
    • Keeps all information internal to the FDA
  • Early Impact:
    • Speeds up clinical protocol reviews and scientific evaluations
    • Helps identify top inspection priorities
  • Functional Capabilities:
    • Summarizes adverse events for safety reviews
    • Performs label comparisons
    • Generates code for nonclinical database development
  • Future Plans:
    • Elsa is the first step in a broader AI strategy
    • More AI tools to be integrated into FDA operations over time, such as data processing and generative-AI functions

Source:

FDA: Press Announcements


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
What are the Prospects and Developments in the Operation of Computerised Systems?

What are the Prospects and Developments in the Operation of Computerised Systems?

Here's the answer:
Read more
Previous
Next